Prurigo Nodularis Improves Following Treatment With Dupilumab - AJMC.com Managed Markets Network

For adult patients living with prurigo nodularis, dupilumab (Dupixent) was shown to significantly improve their skin lesions, quality of life (QOL), and itching, reports a new study in Anais Brasileiros de Dermatologia.1

Dupilumab was approved by the FDA2 on September 29, 2022, as the first treatment for prurigo nodularis, a rare chronic inflammatory skin disease characterized by hard itchy lumps.

"Patients with prurigo nodularis often experience severe itch and thereafter, develop anxiousness about their conditions," the study authors wrote. "This study consecutively enrolled patients who have been diagnosed with [prurigo nodularis] for at least 6 months and have failed to respond to traditional therapies."

The treatment regimen for this study consisted of a 600-mg induction dose of dupilumab, followed by 300 mg administered every other week for at least 16 weeks. Concomitant use of topical glucocorticoids, oral antihistamines, topical antibiotics, and traditional Chinese medicine was permitted. Blood tests performed at weeks 0 and 16 evaluated while blood cell (WBC) count, serum absolute eosinophil count (AEC), and total serum IgE) levels. All patients included in this analysis failed all previous treatments, and their mean (SD) duration of prurigo nodularis was 5.525 (6.6) years; 20 years was the longest duration.

When the study kicked off, every patient had widespread erythematous nodules, with plaques distributed symmetrically on the extremities, hands, and trunk. Most notably, skin lesions abated in 87.5% of the patients by week 16.

Further, by week 16, a complete response (a 3-grade decrease in Investigator's Global Assessment [IGA] score) was seen in 25.0% of the study participants, 50.0% of patients reported a partial response (less than a 2-grade IGA score drop) to dupilumab treatment, and just 1 patient had a poor treatment response, with rashes significantly reduced only on the extensor side of his lower limbs.

In addition, there was an overall reduction in mean IGA scale ratings between weeks 0 and 16 (P < .0001). At week 0, the mean overall IGA score was 3.75 compared with 1.50 by week 16, with 5 patients having an IGA score of 1 at week 16. Subjective improvements were also seen at week 16 for pruritus symptoms, QOL, anxiety, and IgE levels:

  • Numerical Rating Scale Itch Intensity weekly average score at baseline was 8.625 vs 1.563 at week 16 (P < .0001)
  • Dermatology Life Quality Index score at baseline was 15.13 vs 4.625 at week 16 (P < .001)
  • Hospital Anxiety and Depression Scale score at baseline was 14.05 vs 1.000 at week 16 (P < .01)
  • IgE levels were overall reduced in 75.0% of patients, with 50% seeing a mean decrease of 52.58%

No significant differences were seen in either WBCs (P = .4137) or AEC (P = .2438), and there were no adverse events reported for the entire study.

Among the patients, the most common comorbid allergic disorders were allergic rhinitis, chronic urticaria, and asthma; 3 patients also had a family history of allergic disorders. In addition, 62.5% of the study participants (mean [SD] age, 64 [10.3] years) had a comorbidity, with the most common being hypertension in 50.0%.

With the risk of severe adverse effects (AEs) being common among patients being treated for prurigo nodularis, there is a long-lasting, unsatisfied need for a safe and effective treatment for the condition, the study authors noted.

"In this real-life observational study, 16 weeks of dupilumab treatment resulted in statistically significant and clinically meaningful improvements in signs, symptoms, pruritus intensity, anxiety levels, depression levels, and QOL," the authors concluded, "with no cases of AEs reported."

They further highlighted the clinical significance of their findings by noting that their findings echo several previous studies of dupilumab that also reported no AEs.

References

1. Zhang Z, Li S, Wang Y, Zhao J. A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis. An Bras Dermatol. Published online March 23, 2023. doi:10.1016/j.abd.2022.09.008

2. FDA approves first treatment for prurigo nodularis. News release. FDA. September 29, 2022. Accessed March 30, 2023. https://bit.ly/3TSWfwY

Adblock test (Why?)

Comments

Post a Comment

Popular posts from this blog

His Apple Watch warned of an irregular heart rate. Turns out he was having a heart attack | Globalnews.ca - Global News Toronto

Image
A Nova Scotia man is thanking a digital watch for saving his life. Travis Chalmers, of Elmsdale, N.S., said he was outside playing road hockey with his son when he suddenly experienced a "warm sensation" in his chest area and a splitting headache. "I just thought it was a flu or cold coming on and my seasonal allergies had been kicking in. I thought it was flu-like symptoms and shrugged it off," he said. But to Chalmers' surprise, an otherwise laidback afternoon eventually took a scary turn when he glanced at his wrist. A notification from his Apple Watch led him to discover he was experiencing a heart attack. "About a half hour later, I'm laying down with my daughter and my heart rate is still beating out of my chest," he continued, adding that he monitored his heart rate on his Apple Watch for the next few hours. The watch indicated that he was experiencing atrial fibrillation, a rapid heart rhythm that can increase the ris...
Read more

“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more

Image
“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more Opioids in America, Part 3: The other side of the crisis - Greeley Tribune Posted: 31 Oct 2020 04:20 PM PDT Editor's Note: This is Part 3 of a three-part series looking into the opioid epidemic across the U.S., rehabilitation options in Weld County and stories from people who have overcome or are currently fighting addiction to opioids. Like many things, there's another side to the opioid crisis. While the addiction to opioids is a problem that needs to be addressed, people who are using the drugs exclusively as prescribed — and who still truly need it from a medical perspective — have been swept up in what some have seen as government's knee-jerk reaction to the crisis. In having their ability limited to get the drugs they need in order to function, many of these patients are left suffering debilitating pain. Richard Mark VanWormer w...
Read more

“A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times” plus 1 more

Image
“A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times” plus 1 more A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times Posted: 12 Dec 2019 11:25 AM PST It was chest pain that brought the 34-year-old woman to the emergency room at Montefiore Medical Center in the Bronx. She'd been coughing for days, but that morning the pain was so bad she was worried that it had turned into pneumonia. She tried to tough it out, but when it was no better by the end of the day, she decided to go to the E.R. It took a few hours, but finally the physician assistant caring for her in the E.R. brought some good news. She didn't have pneumonia; she didn't have a clot in her lungs. This was just muscle strain from coughing. The year before, she was told she had asthma. She was given inhalers to stop the coughing and wheezing, but they didn't seem to do much. So she didn'...
Read more